This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
by Zacks Equity Research
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
RGNXPositive Net Change ABBVNegative Net Change ACIUNegative Net Change AMRXPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
by Kanishka Das
Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
IMCRNegative Net Change BMYNegative Net Change MRKNegative Net Change
biotechs
Will LQDA's Differentiated PAH Approach Drive Growth?
by Ekta Bagri
LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
LQDAPositive Net Change JNJNegative Net Change UTHRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Moderna Stock Following Its Cancer Breakthrough?
by Sundeep Ganoria
MRNA's cancer therapy scores a phase III win, strengthening its mRNA platform, while pipeline risks and competition remain key concerns.
MRNANegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
by Ahan Chakraborty
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
KROSNegative Net Change SRPTPositive Net Change PTCTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
by Ahan Chakraborty
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
KROSNegative Net Change SRPTPositive Net Change PTCTNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
by Zacks Equity Research
GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
GSKNegative Net Change RGENNegative Net Change ANIKPositive Net Change ANABNegative Net Change
biotechs
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
by Zacks Equity Research
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
ACADNegative Net Change RGENNegative Net Change ACIUNegative Net Change AMRXPositive Net Change
biotechnology biotechs medical pharmaceuticals
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
by Ahan Chakraborty
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
BEAMNegative Net Change EDITNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
HALO Stock Rises 36% in a Month: Here's What You Should Know
by Zacks Equity Research
Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
HALONegative Net Change JNJNegative Net Change RGENNegative Net Change ARGXPositive Net Change
biotechs